

DETERMINATION OF NON-ADHERENCE IN PATIENTS RECEIVING ELTROMBOPAG

Marija Pendovska^{1,4*}, Irina Panovska Stavridis¹, Svetlana Krstevska Balkanov¹, Marija Popova Labacevska¹, Zlate Stojanoski¹, Marija Nadziska², Mihail Aleksandrov^{3,4}, Biljana Lazarova⁴, Viktorija Maksimova⁴

¹ PHO University Clinic of Hematology, Ss. Cyril and Methodius University, Blvd. Majka Tereza 17, 1000 Skopje, Republic of North Macedonia

² PHO Institute for Lung Diseases in Children KOZLE, 1000 Skopje, Republic of North Macedonia

³ Department of production, research & development, "TetraHip LLC Kocani", Orizova 9, 2300 Kocani, Republic of North Macedonia

⁴ Faculty of Medical Sciences, Goce Delcev University, Krste Misirkov 10-A, 2000 Stip, Republic of North Macedonia

*Corresponding author: marija.311156@student.ugd.edu.mk, marija.hemato@gmail.com

Introduction


Eltrombopag, an orally administered thrombopoietin receptor agonist, selectively binds to the transmembrane domain of the thrombopoietin receptor on the surface of platelets, megakaryocytes and megakaryocyte precursor cells (1). The aim of our research is to determine patient non-adherence and its impact on the effectiveness and safety of prescribed therapy, as well as the possibility of treatment failure.

Materials and Methods

The observational, longitudinal, and retrospective study was conducted in the PHO University Clinic of Hematology in Skopje, R.N.Macedonia. 17 patients (9 men and 8 women) were followed from January to August 2023. Five of them were with diagnose aplastic anemia and 12 with immune thrombocytopenia. All of them treated with Eltrombopag. Systematically reviewed medical records were performed from the Department of Hospital pharmacy that collected anamnestic data.

Results

The results from the study, related with dose frequency, double taking therapy, possibility of drug-drug interactions and food/supplement-drug interactions, and omitted doses are showed in Graphicone 1. Briefly, thirteen types of non-adherence were identified, of which 3 (23,08%) were related to dose frequency, 1 (7,69 %) was related to double taking therapy, 5 (38,46%) were related to the possibility of drug-drug interactions, 2 (15,38%) with possibility for food/supplement-drug interactions and 2 (15,38 %) omitted doses.



Graphicone 1. Results from determination of non-adherence in patients receiving Eltrombopag

Conclusion

The clinical pharmacist intervention can improve patient adherence, because the most important determinants effectiveness and safety are adherence to the prescribed therapy, multiple drug and food/supplement interactions which can vary on dose-response relationship, and risk of insufficient effectiveness of therapy (2). Failure to adherence is a serious problem which not only affects the patient but also the health care system.

References

1. Garnock-Jones, K.P. and Keam, S.J. Eltrombopag. *Drugs*; 2009; 69(5):567-76. doi: 10.2165/00003495-200969050-00005.
2. Spinewine, A., et al. The Role of Pharmacists in Optimising Drug Therapy; 2023; pp 105–117.

